Short Link N promotes disc repair in a rabbit model of disc degeneration
Authors:
- Fackson MwaleFMFackson Mwale
- Koichi MasudaKMKoichi Masuda
- Michael P. GrantMGMichael P. Grant
- Laura M. EpureLELaura M. Epure
- Kenji KatoKKKenji Kato
- Shingo MiyazakiSMShingo Miyazaki
- Kevin ChengKCKevin Cheng
- Junichi YamadaJYJunichi Yamada
- Won C. BaeWBWon C. Bae
- Carol MuehlemanCMCarol Muehleman
- Peter J. RoughleyPRPeter J. Roughley
- John AntoniouJAJohn Antoniou
Open Access
- 29 August 2018
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 201
Abstract
The degeneration of the intervertebral disc (IVD) is characterized by proteolytic degradation of the extracellular matrix, and its repair requires the production of an extracellular matrix with a high proteoglycan-to-collagen ratio characteristic of a nucleus pulposus (NP)-like phenotype in vivo. At the moment, there is no medical treatment to reverse or even retard disc degeneration. The purpose of the present study was to determine if a low dose of short link N (sLN), a recently discovered fragment of the link N peptide, could behave in a manner similar to that of link N in restoring the proteoglycan content and proteoglycan-to-collagen ratio of the disc in a rabbit model of IVD degeneration, as an indication of its potential therapeutic benefit in reversing disc degeneration. Adolescent New Zealand white rabbits received an annular puncture with an 18-gauge needle into two noncontiguous discs to induce disc degeneration. Two weeks later, either saline (10 μL) or sLN (25 μg in 10 μL saline) was injected into the center of the NP. The sLN concentration was empirically chosen at a lower molar concentration equivalent to half that of link N (100 μg in 10 μL). The effect on radiographic, biochemical and histologic changes were evaluated. Following needle puncture, disc height decreased by about 25–30% within 2 weeks and maintained this loss for the duration of the 12-week study; a single 25-μg sLN injection at 2 weeks partially restored this loss in disc height. sLN injection led to an increase in glycosaminoglycans (GAG) content 12 weeks post-injection in both the NP and annulus fibrosus (AF). There was a trend towards maintaining control disc collagen-content with sLN supplementation and the GAG-to-collagen ratio in the NP was increased when compared to the saline group. When administered to the degenerative disc in vivo, sLN injection leads to an increase in proteoglycan content and a trend towards maintaining control disc collagen content in both the NP and AF. This is similar to link N when it is administered to the degenerative disc. Thus, pharmacologically, sLN supplementation could be a novel therapeutic approach for treating disc degeneration.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 46 references indexed in Scilit:
- The efficacy of Link N as a mediator of repair in a rabbit model of intervertebral disc degenerationArthritis Research & Therapy, 2011
- The Twin Spine Study: Contributions to a changing view of disc degeneration†The Spine Journal, 2009
- Biological repair of the degenerated intervertebral disc by the injection of growth factorsEuropean Spine Journal, 2008
- IntroductionSpine, 2004
- In Vivo Growth Factor Treatment of Degenerated Intervertebral DiscsSpine, 2004
- Prolonged Spinal Loading Induces Matrix Metalloproteinase-2 Activation in Intervertebral DiscsSpine, 2003
- Matrix Metalloproteinases And AggrecanaseSpine, 2000
- Matrix Metalloproteinases: The Clue to Intervertebral Disc Degeneration?Spine, 1998
- Toward a Biochemical Understanding of Human Intervertebral Disc Degeneration and HerniationSpine, 1997
- The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration.Journal of Clinical Investigation, 1996